Recently, several humanized monoclonal antibodies have been developed for targeted therapies, including anti-TSLP (tezepelumab) [25,48,57,59] and anti-TSLPR (verekitug) as part of the immune system response pathways associated with chronic inflammation such as CRSwNP [60,61,62]. Here, TSLP is linked to chronic rhinosinusitis with nasal polyps.